Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  2. Drug

    Iopofosine I-131

    go.drugbank.com/drugs/DB15244
    Investigational

    Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).

    Synonyms: Ethanaminium, 2-((hydroxy((18-(4-(iodo-131I)phenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner salt, 2-((HYDROXY((18-(4-(131I)IODOPHENYL)OCTADECYL)OXY)PHOSPHINYL)OXY)-N,N,NTRIMETHYLETHANAMINIUM INNER SALT
  3. Drug

    Lobeline

    go.drugbank.com/drugs/DB05137
    Investigational

    An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.

  4. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

  5. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. … Mevastatin is a pro-drug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.

  6. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

  7. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

  8. Drug

    SR-9011

    go.drugbank.com/drugs/DB14014
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

    Synonyms: 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-
  9. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  10. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic